Alcon AG vs ARK Autonomous Technology & Robotics ETF — how do they compare? Alcon AG trades at $74.32 (market cap $36.44B), while ARK Autonomous Technology & Robotics ETF trades at $128.66. The key difference: Alcon AG pays a 0.48% dividend while ARK Autonomous Technology & Robotics ETF pays none, and ARK Autonomous Technology & Robotics ETF is trading nearer its 52-week high, Alcon AG nearer its low. Which is the better fit depends on your goals.
| ALC | ARKQ | |
|---|---|---|
Market Cap | $36.44B | — |
Sector | Health | Sector/Thematic |
52-Week High | $90.12 | $143.82 |
52-Week Low | $62.02 | $95.28 |
Enterprise Value | $40.28B | — |
Dividend Yield | 0.48% | — |
Signals from Pluang's Aura AI — not financial advice
ALC trades at $73.59, down slightly by 0.05% today, with a bullish technical signal from moving averages and a consensus analyst price target of $86.67 implying 17.8% upside. Recent Q2 2026 earnings beat estimates with EPS of $0.84 versus $0.77 expected, and the company raised its 2026 profitability outlook, driving positive investor sentiment. Revenue growth has been steady, reaching $10.40 billion in 2025, though net income margin dipped to 5.92%.
The outlook is positive given strong earnings beats, raised guidance, and bullish analyst ratings, but risks include elevated P/E of 57.52, high RSI levels suggesting overbought conditions, and margin pressures from rising costs. Institutional ownership trends and recent collaborations, like with RxSight, support growth, yet macroeconomic and competitive factors warrant caution.
ARKQ trades at $128.93, up 0.81% today, with a bullish technical signal from moving averages but neutral oscillators. The ETF focuses on autonomous technology and robotics, with recent news highlighting its exposure to SpaceX and defense stocks. Support sits at $126, resistance at $129.
Outlook is cautiously optimistic due to thematic growth in AI and robotics, though high RSI suggests near-term overbought conditions. Risks include sector volatility and reliance on disruptive tech trends. Analysts view it as a hold with long-term accumulation potential amid market swings.
Trailing returns across standard periods
Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan.
Read more on ALC →ARKQ is an actively managed ETF that invests in autonomous technology and robotics. It focuses on disruptive innovations like autonomous mobility, electric vehicles, 3D printing, and energy storage, with holdings such as Tesla and Teradyne.
Read more on ARKQ →